Melanie Goldfarb, MD, MSc, FACS, FACE, FSSO, discusses the importance of survivorship and providing care to patients with thyroid cancer.
Melanie Goldfarb, MD, MSc, FACS, FACE, FSSO, Center for Endocrine Tumors, Providence Saint John's Cancer Institute, discusses the importance of survivorship and providing care to patients with thyroid cancer.
There have recently been multiple articles and symposiums highlighting the importance of survivorship for patients with thyroid cancer. According to Goldfarb, survivorship is defined as the time from diagnosis.
It is important to highlight this topic as long-term survivorship care aids in reducing anxiety, emergency hospital visits, and health care costs, for patients across various cancer types, including thyroid cancer.
Transcription:
0:08 | There's been a couple different articles and symposiums proposed and finally [last] year, we [had] a full survivorship symposium, which is really exciting. It’s important because anybody that gets thyroid cancer is a thyroid cancer survivor, so survivorship is from the time of diagnosis. Even more so for thyroid cancer patients, they live a lifetime for the most part, so every year there's more and more thyroid cancer survivors.
0:43 | But even if you're surviving, that doesn't mean that you don't have physical, emotional, psychosocial, and things going on that are important to be acknowledged, addressed, and dealt with. In the cancer community until 10-15 years ago on all cancers, it was like, great, let's keep you alive. But now as more and more people are survivors and living longer, what survivorship means and all the other things are coming to the forefront.
1:17 | Same thing especially in the thyroid world, because they're not usually taken care of in the oncology space. All of these survivorship things are not always available or not always brought up. [Experts say,] you have thyroid cancer, great, you're done, and don't acknowledge that a lot of the patients have a lot of other things going on.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
Post Hoc and Real-World Analyses Explore Benefit of Lenvatinib in DTC
December 5th 2024During a Case-Based Roundtable® event, Lori J. Wirth, discussed recent analyses that have developed a better understanding of the outcomes with lenvatinib in differentiated thyroid cancer in the second article of a 2-part series.
Read More